Ihr Ausdruck wurde in der folgenden Navigationsebene erstellt:
Interfaculty Center for Pharmacogenomics and Drug Research (IZEPHA)
The Interfaculty Center for Pharmacogenomics and Drug Research (IZEPHA) is a cooperative enterprise established by the Faculty of Medicine, the Faculty of Chemistry and Pharmacy and the University Hospital in Tübingen together with the Robert Bosch Foundation and the Robert Bosch Hospital in Stuttgart.
The research groups are supported by means of so-called "Twinning Grants" involving one project partner each from Tübingen or Stuttgart.
IZEPHA has set itself the task of developing and intensifying the spectrum of collaborative research, teaching and advanced training in the area of drug sciences, pharmacology and clinical pharmacology. In particular, researchers at IZEPHA are focusing on topics that lie in the fields of infectiology, oncology, diseases associated with immunology and inflammation and metabolism-related vascular diseases.
The Twinning Grants are financed by the Robert Bosch Foundation, the University of Tübingen and the Faculty of Medicine in Tübingen; primarily, their purpose is to provide start-up funding for setting up cooperative projects and raising third-party funds.
| Project |
Partner in Tübingen |
Partner in Stuttgart |
|---|---|---|
|
Pharmacogenomics of bile acid transporters and bile acid-regulated nuclear receptors in the pathogenesis of human nonalcoholic fatty liver disease |
PD Dr. N. Stefan Department of Internal Medicine IV |
Dr. O. Burk IKP |
|
PIVOT - PET Imaging for in Vivo Evaluation of Drug Transport Further information (pdf 26 KB) |
Prof. Dr. B. Pichler Clinic for Radiology |
Prof. Dr. M. Schwab IKP |
|
Pharmacogenomics of the novel proton/organic cation antiporter MATE1 (multidrug and toxin compound extrusion): impact on drug absorption, distribution, metabolism, and elimination Further information (pdf 26 KB) |
PD Dr. M. Sausbier Faculty of Chemistry and Pharmacy |
Dr. E. Schäffeler IKP |
|
Novel Strategies in drug therapy of inflammatory bowel diseases |
Prof. Dr. P. Ruth Faculty of Chemistry and Pharmacy |
Dr. J. Wehkamp IKP |
|
Impact of individual variation in drug transporters for better prediction of response to the tyrosine kinase inhibitor imatinib in gastrointestinal stromal tumors (GISTs) Further information (pdf 26 KB) |
PD Dr. Dr. F. Mayer Department of Internal Medicine II |
PD Dr. A. Nies IKP |
|
Specific therapeutic targeting of primary malignancies of the liver enabled by controlled transient depletion of ATP Further information (pdf 47 KB) |
Prof. Dr. U. Lauer Department of Internal Medicine I |
Dr. K. Klein IKP |
|
Genetic and non-genetic factors influencing the pharmacokinetics of artesunate given intramuscularly or intravenously to children with severe malaria |
PD Dr. J. Kun Institute for Tropical Medicine |
Dr. R. Kerb IKP |
|
Melastatin in growth control of melanoma |
PD Dr. C. Harteneck Institute of Pharmacology and Toxicology |
Dr. R. Kerb IKP |
|
Efficacy, distribution and pre-systemic elimination of systemically and topically administered p38-MAP-Kinase inhibitors in the treatment of COPD |
Prof. Dr. S. Laufer Faculty of Chemistry and Pharmacy |
Dr. T. Mürdter IKP |
|
Analysis of specific genetic alterations in routine formalin fixed paraffin-embedded tissues as an adjunct in the precise definiton of malignant tumors Further information (pdf 26 KB) |
Prof. Dr. F. Fend Institute of Pathology |
Prof. Dr. G. Ott
|
IKP, Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology
